Trial FOMO: Enrollment Closed

You refreshed clinicaltrials.gov daily for a cohort that filled before you'd even learned the molecule's name.

Filed under Retatrutide ·Survodutide ·Orforglipron · #fomo ·#trial-cope ·#glp-1

Active Compounds

Retatrutide · Triple GIP/GLP-1/Glucagon Receptor Agonist

An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

Orforglipron · Incretin Mimetic

Foundayo (orforglipron) is Eli Lilly's oral small-molecule GLP-1 receptor agonist. Phase 3 trials show up to 11.2% weight loss via daily pill — no injections required. Regulatory submissions expected 2026.

RX: Retatrutide · Survodutide · Orforglipron
Dosage: 0 participants enrolled
Half-life: until Phase 3 readout
Source: manual
Tags: fomo , trial-cope , glp-1
Stamped: 2026-05-04 · Cycle 018
Lot #: LOT-20260504T00:59:30.805Z